Taysha Gene Therapies Files 8-K
Ticker: TSHA · Form: 8-K · Filed: Aug 12, 2024 · CIK: 1806310
Sentiment: neutral
Topics: 8-K, financial-reporting
TL;DR
Taysha Gene Therapies filed an 8-K on Aug 12, 2024, reporting financial condition and results. Details TBD.
AI Summary
Taysha Gene Therapies, Inc. filed an 8-K on August 12, 2024, reporting on its results of operations and financial condition, as well as financial statements and exhibits. The filing does not contain specific financial figures or operational details within the provided text, but indicates a formal reporting event.
Why It Matters
This 8-K filing signals that Taysha Gene Therapies is providing updated information to the SEC regarding its financial condition and operations, which is crucial for investors to assess the company's status.
Risk Assessment
Risk Level: low — The filing is a standard corporate disclosure and does not inherently present new risks, but the content of the report itself could contain material information.
Key Players & Entities
- Taysha Gene Therapies, Inc. (company) — Registrant
- August 12, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- 3000 Pegasus Park Drive, Suite 1430, Dallas, Texas 75247 (address) — Principal Executive Offices
FAQ
What specific financial results or operational updates are detailed in this 8-K filing?
The provided text of the 8-K filing indicates it pertains to 'Results of Operations and Financial Condition' and 'Financial Statements and Exhibits,' but does not include the specific financial figures or operational details within this excerpt.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on August 12, 2024.
What is the principal business address of Taysha Gene Therapies, Inc.?
The principal executive offices of Taysha Gene Therapies, Inc. are located at 3000 Pegasus Park Drive, Suite 1430, Dallas, Texas 75247.
Under which section of the Securities Exchange Act is this report filed?
This report is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
What is the SIC code for Taysha Gene Therapies, Inc.?
The Standard Industrial Classification (SIC) code for Taysha Gene Therapies, Inc. is 2836, which corresponds to Biological Products (No Diagnostic Substances).
Filing Stats: 530 words · 2 min read · ~2 pages · Grade level 10.7 · Accepted 2024-08-12 08:05:53
Key Financial Figures
- $0.00001 — nge on which registered Common Stock, $0.00001 par value TSHA The Nasdaq Stock Mar
Filing Documents
- d760391d8k.htm (8-K) — 26KB
- d760391dex991.htm (EX-99.1) — 82KB
- 0001193125-24-198392.txt ( ) — 243KB
- tsha-20240812.xsd (EX-101.SCH) — 3KB
- tsha-20240812_lab.xml (EX-101.LAB) — 18KB
- tsha-20240812_pre.xml (EX-101.PRE) — 11KB
- d760391d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release, dated August 12, 2024. 104 Cover Page Interactive Data File (the cover page XBRL tags are embedded within the inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Taysha Gene Therapies, Inc. Dated: August 12, 2024 By: /s/ Kamran Alam Kamran Alam Chief Financial Officer